Articles tagged with Antibodies
Researchers at TSRI have developed a more effective nicotine vaccine by targeting only the left-handed version of nicotine, eliciting four times as many antibodies. The new vaccine has shown promise in animal studies and could lead to treatments for smoking addiction.
Researchers at University of Cincinnati discover a new drug therapy that effectively lowers antibodies in kidney patients, paving the way for more successful kidney transplants. The study suggests this approach could benefit up to 10-20% of heart and pancreas transplant candidates who are currently ineligible due to high antibody levels.
Researchers found that endogenous retroviruses play a critical role in the body's immune defense against common bacterial and viral pathogens. The ERV DNA can activate B cells to produce protective antibodies, suggesting that these viruses have an 'physiological' function.
Researchers at Yale University have developed synthetic antibody mimics (SyAMs) that target disease cells and stimulate immune responses, offering potential for treating prostate cancer and other diseases.
Researchers at the University of Southampton have found that a specific form of antibody, IgG2B, is more effective at stimulating cancer immunity than others. By engineering antibodies into a locked B structure, they aim to create stronger immune stimulators for cancer patients.
A study found that seasonal flu vaccines protect against multiple flu strains, including those not included in vaccine formulations. The researchers also discovered that exposure to birds can elicit immune responses to avian influenza viruses in humans.
A study found that seasonal flu vaccines can induce strong immune responses against multiple flu virus subtypes, including some not included in vaccine formulations. This could provide protection against emerging pandemic strains from avian populations.
Research team led by Miguel Soares discovered that specific bacterial components in the human gut microbiota can trigger a natural defense mechanism against malaria. High levels of circulating anti-alpha-gal antibodies induced by vaccination are highly protective against malaria transmission.
Ramy Arnaout has been awarded a two-year grant to analyze antibody repertoires of over 1,000 Americans to clarify the link between antibodies, cardiovascular disease, and aging. The goal is to determine individual treatment needs for patients with cardiovascular disease.
A team of researchers from the University of Surrey has identified a rogue protein in multiple sclerosis, which attacks the body's central nervous system. The discovery could lead to a better understanding of the disease and new treatments against neurodegenerative diseases.
Patients with a history of heparin-induced thrombocytopenia (HIT) may be ready for urgent heart surgery sooner than previously thought, according to new research. A combination of appropriate blood screenings and therapeutic plasma exchange can help lower HIT antibody levels quickly.
Researchers found that therapeutic plasma exchange can rapidly reduce HIT antibody levels, making patients eligible for urgent cardiac surgery sooner. The study suggests using both functional and immunoassays to determine patient readiness, with the functional assay indicating lower antibody levels more quickly.
Researchers at Scripps Research Institute have identified vulnerable sites on the surface of Ebola virus that are targeted by the antibodies in ZMapp, a drug cocktail administered to patients during the 2014 outbreak. The study provides insights into how ZMapp works and suggests strategies to improve it.
Researchers developed a system to identify high-affinity nanobodies, which can precisely target specific molecules. This allows scientists to select the best nanobodies, eliminate cross-reactive ones, and generate super-high-affinity dimers for therapeutic or diagnostic applications.
A new single-domain antibody called FC5 has proven able to cross the blood-brain barrier, opening doors to new treatments for brain diseases. This breakthrough technology allows for the delivery of larger molecules into the brain, targeting conditions such as Alzheimer's, Parkinson's, and cancer.
A study found that Staphylococcus aureus uses protein A as a superantigen to activate many B cells, leading to immune tunnel vision and reduced protection against infection. This knowledge can inform future vaccine approaches to combat MRSA.
Researchers identify a bacterial protein that mimics the satiety hormone, leading to variations in food intake. A blood test for this protein could lead to specific treatments for eating disorders, while neutralizing the protein may prevent dysregulation of food intake.
A new blood test has been identified as a potential predictor for focal segmental glomerulosclerosis (FSGS), a devastating form of kidney disease. The test, called FAST, uses high-density protein tests to detect antibodies against specific antigens that are significantly increased in patients at risk for FSGS.
Kidney transplant recipients infected with BK virus are more likely to develop donor-specific antibodies, which can lead to organ rejection. The study found a significant association between persistent BK infections and the development of these detrimental antibodies.
Researchers have successfully delivered antibody mimics into cells using a disarmed version of anthrax toxin, offering a potential new approach for treating various diseases. The development demonstrates the first effective delivery of antibodies into cells, which could lead to novel drug treatments.
Researchers at Caltech have developed a new technique called vectored immunoprophylaxis (VIP) to prevent the spread of diseases like HIV, malaria, and influenza. This method provides specific antibodies that can neutralize pathogens, offering a potential solution for widespread use in the less developed world.
A new study reveals that gut microbes play a vital role in stimulating protective immune responses to the seasonal flu vaccine. Researchers found that mice with altered gut microbiota showed reduced antibody responses to vaccination, highlighting the importance of gut microbes in vaccine efficacy.
A new study uses genetically modified plants to teach the immune system to tolerate clotting factors, reducing the risk of antibody formation. The treatment, which involves feeding mice with plant capsules, has shown promising results and may offer a cost-effective alternative to current treatments.
Scientists from A*STAR's Bioprocessing Technology Institute uncover crucial role of DOK3 and SHP1 in plasma cell development and production. This discovery advances understanding of plasma cells and antibody response, potentially leading to improved treatment for patients with autoimmune diseases like lupus and multiple myeloma.
Researchers develop a potential therapy for Sudan ebolavirus, showing promising results in laboratory tests and mouse models. The humanized antibody has been identified as an immunotherapeutic candidate to treat SUDV infection.
Researchers at MIPT and RAS made a significant step towards creating medical nanorobots by enabling nanoparticles to produce logical calculations. The discovery paves the way for biomedical technologies, including selective binding to target cells and analyzing biological materials.
A new study by Johns Hopkins Medicine found that nearly one in ten inner-city children has a food allergy, with breastfed kids and high exposure to endotoxin being potential risk factors. The study also highlighted a subgroup of children with higher-than-average allergy risk.
A new virus-like particle vaccine has shown promising results in a human trial, generating antibodies that provide long-term protection against chikungunya. The vaccine, composed of non-infectious VLP particles, was well-tolerated and effective across different doses.
A study led by Johns Hopkins Medicine found that at least one in 10 inner-city children has a food allergy, with peanuts being the most common allergen. The study also suggests that early-life exposure to certain microbes may play a protective role against food allergies.
Researchers found that the HIV virus's outer envelope is mistaken for bacterial antigens by the immune system, leading to ineffective antibodies. The study suggests a new hypothesis for how HIV vaccine development could be improved by targeting the gut flora.
Researchers discovered that a specific type of IgG2 antibody protects Pseudomonas aeruginosa by binding to extra-long sugars on the bacterial surface. This protection can lead to reduced antibacterial capacity and worsened disease outcomes in immunized individuals.
Researchers at Johns Hopkins Bloomberg School of Public Health have found a potential new path toward malaria immunization by injecting a vaccine-like compound into mice. The approach, known as Vector Immunoprophylaxis (VIP), triggers the creation of antibodies that prevent malaria in 70% of mice.
Ashley Anh Vo, a transplant pharmacist at Cedars-Sinai, received the 2014 Clinician of Distinction award for her work on anti-rejection drugs. Her research identified IVIG as an effective therapy to reduce HLA antibody levels and prolong patient survival.
Researchers discovered new vaccine targets that could help combat malaria by identifying previously untested antigens and gaining insights into antigen combination. A group of infected children was followed over six months to identify combinations of antibodies providing up to 100% protection against clinical episodes.
Aarhus University researchers have created an easier method to tag proteins with DNA, enhancing diagnostic techniques, nanotechnology, and disease treatment. The new method allows for controlled conjugation of macromolecules, making it possible to attach chemotherapeutics to antibodies while preserving their recognition element.
A potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine has been identified. The biomarker, anti-C5/gp41732-744 antibody levels above 4μg/ml, may be able to predict which patients will benefit most from the therapeutic HIV vaccine candidate Vacc-4x.
A new anti-EGFR antibody has been successfully tested on canine cancer cells, offering a promising approach to diagnosis and treatment. The antibody, developed from its human counterpart, demonstrates high specificity and is expected to improve cancer treatment outcomes for dogs.
Researchers at EPFL have created a new method to track down allergens in foods, which can help develop customized therapies and provide higher accuracy than conventional allergy-testing methods. The method uses immunoaffinity capillary electrophoresis and mass spectrometry to identify specific proteins causing allergic reactions.
Whitehead Institute scientists have genetically modified red blood cells to carry valuable payloads, including drugs, vaccines, and imaging agents. The approach uses sortagging, a protein-labeling technique that establishes strong chemical bonds between surface proteins and therapeutic substances.
Researchers discovered a mini-antibody called 3D8 scFv that can degrade viral DNA and RNA regardless of specific sequences, protecting mammalian cells and genetically manipulated mice against different viruses. The correct dose is crucial to destroy only viral components, not host genetic material.
The global HIV epidemic has seen significant reductions in new infections and AIDS-related deaths thanks to advancements in prevention strategies such as clean needles and condom use, and effective treatment that reduces infectiousness.
Researchers at NIAID have developed a vaccine that delivers the AMA1-RON2 complex, protecting mice from lethal malaria. The improved antibody response to this vaccine provides protection against infection even in non-vaccinated animals.
A new study published in PNAS reveals how the GAD65 protein changes shape when activated, potentially linking it to type 1 diabetes. The research found that antibodies interact with the protein differently depending on its state, which may affect vaccine development for the disease.
A Kaiser Permanente study published in the Journal of Clinical Oncology found that patients with small HER2+ breast cancer tumors (<0.5 cm) had a high survival rate without distant recurrence, even without treatment. For larger tumors (0.6-1 cm), the risk was slightly lower but still remained low.
The investigational agent DMOT4039A, a combination of chemotherapeutic agent and antibody, showed initial evidence of anti-cancer activity in a phase I clinical trial for pancreatic and ovarian cancers. The drug targets mesothelin-rich cancer cells, reducing the risk of off-target effects.
Researchers have discovered how lemurs fight the Cryptosporidium parasite using next-generation sequencing technology. This breakthrough could aid in conservation efforts and develop new methods for detecting and treating the infection.
Researchers discovered that pigs from infected mothers suffer less from the infection than those from non-infected mothers. The study found that maternal antibodies in the sow's milk protect piglets from infections in the first few weeks of life, leading to fewer cases of severe diarrhoea and faster recovery.
Researchers at McMaster University have successfully tested an antibody that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs. The study found that blocking a specific protein in the lungs with an antibody alleviates baseline inflammation and provides resistance to allergens.
Researchers discovered that shark antibodies possess structural characteristics making them robust against dehydration, leading to enhanced stability in human antibody fragments. This breakthrough enables the development of improved therapeutic and diagnostic antibodies with increased efficacy.
Researchers found that galectins recognize and kill bacteria with similar carbohydrate coatings, filling gaps in immune defenses. This discovery could lead to the development of new antibiotics for treating certain bacterial infections.
The collaboration aims to overcome barriers in delivering antibodies directly into the brain to treat dementia, Alzheimer's disease and other neurological disorders. The project will utilize Nanomerics' Molecular Envelope Technology to develop effective treatments with potential to improve patient adherence and quality of life.
Scientists have found that targeting adhesion molecule CD146 with anti-CD146 antibody AA98 shows promise in reducing inflammation and tumor incidence in mice with colitis. The study suggests that CD146 plays a dual role in promoting inflammation, making it a potential therapeutic target for treating inflammatory bowel disease and preve...
A recent NIH study found that a rare genetic disorder, CDG-IIb, can confer resistance to severe or recurrent viral infections like HIV and influenza. The researchers discovered that these viruses replicate less efficiently in cells with the disease, creating fewer and less infectious viruses.
Researchers developed tiny biomolecular tweezers to study mechanical forces' impact on cell and protein activity. The devices precisely stretch cells and molecules, allowing simultaneous analysis of multiple samples, enabling high-throughput assessment of force effects on a broad scale.
A recent study in Human Vaccines & Immunotherapeutics found that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix are non-inferior to three doses, providing similar protection against cervical cancer. The two-dose schedule showed a clinically acceptable safety profile and induced strong antibody responses.
IRC Researchers discover a new function of AID, an enzyme crucial for the immune response. This finding helps explain hyper-IgM syndrome type 2 (HIGM2), a rare genetic disorder that causes an immunodeficiency syndrome.
Researchers use shrink wrap to boost signal of fluorescent markers in biosensing, enabling detection of infectious diseases with lower limits of detection. The technique could lead to a low-cost, highly sensitive diagnostic device using common, everyday materials.
The NIH has awarded a five-year grant of up to $28 million to establish a center for excellence in finding an antibody cocktail to fight the deadly Ebola virus. Researchers from 15 institutions, led by Erica Ollmann Saphire at Scripps Research Institute, will collaborate on definitive experiments.
Researchers have identified a subclass of antibodies associated with an effective immune response to an HIV vaccine. The study provides key insights that could aid the development of new vaccines, focusing on understanding the underlying quality of the immune response.
Two studies found that only one subclass of V1V2-directed IgG antibodies, the IgG3 subclass, is associated with antiviral responses linked to the reduced risk of HIV infection seen in the RV144 trial. More research is needed to determine whether these antibodies protected some vaccinees from HIV infection.